drugset / Trial / NCT01002079

Drug-Drug Interaction Study With Rifampin

NCT01002079

Phase 1 Completed 20 enrolled Bristol-Myers Squibb PRA Health Sciences · collab
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to determine if the concomitant administration of rifampin with BMS-708163 will affect the Pharmacokinetics of BMS-708163 and to assess safety and tolerability of co-administration BMS-708163 and rifampin

Timeline

Start
2010-08
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Avagacestat Small molecule 125 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications